Treatment of patients with plaque psoriasis with secukinumab in a real-life setting: a 52-week, multicenter, retrospective study in Spain

The Journal of Dermatological Treatment
Jaime NotarioM Ferran

Abstract

Background: The efficacy and safety of secukinumab in patients with plaque psoriasis (PsO) have been demonstrated in randomized clinical trials (RCTs). However, data regarding its efficacy and safety in real-life settings are scarce. Objectives: To evaluate the efficacy and safety of secukinumab in clinical practice in patients with PsO attending 10 dermatology centers in Spain. Methods: Data from 136 patients consecutively treated with secukinumab for at least 52 weeks were collected in a retrospective observational study. Results: After 52 weeks of treatment, 69% and 46% of patients achieved a PASI-75, PASI-90, respectively. PASI-score ≤5 was achieved in 83% of patients, PASI-score ≤3 in 73% and PASI-score ≤1 in 47%. Response rates were found significantly lower in patients with obesity and non-naïve to biologics (p < .05). The most common adverse event (AE) was candidiasis (5/136). Thirty-six patients (26.5%) discontinued treatment by week 52 due to lack or loss of response (n = 29), AEs (n = 2) or other causes (n = 5). Conclusion: These findings complement the efficacy and safety profiles of secukinumab in PsO outlined in RCTs. The effectiveness in clinical practice may be lower in patients with a BMI ≥30 and those previous...Continue Reading

References

Dec 18, 2003·British Journal of Clinical Pharmacology·A A Mangoni, S H D Jackson
Mar 24, 2004·Micron : the International Research and Review Journal for Microscopy·Terence Ryan
Apr 16, 2004·The Journal of Investigative Dermatology. Symposium Proceedings·John de KorteJan D Bos
Jul 31, 2007·Lancet·Christopher Em Griffiths, Jonathan Nwn Barker
Mar 4, 2008·Journal of the American Academy of Dermatology·Alexa B KimballUNKNOWN National Psoriasis Foundation
Jul 10, 2014·The New England Journal of Medicine·Richard G LangleyUNKNOWN FIXTURE Study Group
Feb 5, 2015·Drugs·Mark Sanford, Kate McKeage
Jul 12, 2017·Journal of the European Academy of Dermatology and Venereology : JEADV·J R GeorgakopoulosJ Yeung
Nov 29, 2017·Journal of the American Academy of Dermatology·Jorge R GeorgakopoulosJensen Yeung
Feb 7, 2018·Acta Dermato-venereologica·Juul M P A van den ReekElke M G J de Jong

❮ Previous
Next ❯

Citations

Dec 28, 2018·Expert Opinion on Pharmacotherapy·Michael S HeathSteven R Feldman
Mar 23, 2019·The Journal of Dermatological Treatment·Kevin K WuJashin J Wu
Apr 21, 2019·The British Journal of Dermatology·P GisondiG Girolomoni
Jan 11, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·M AugustinC Peralta
May 29, 2020·Expert Opinion on Biological Therapy·Paolo Gisondi, Giampiero Girolomoni
Dec 1, 2019·Journal of the European Academy of Dermatology and Venereology : JEADV·K ReichG Di Comite
Oct 20, 2020·The Journal of Dermatological Treatment·Fatma Elif Yıldırım, Fatma Aslı Hapa
Nov 11, 2020·Expert Opinion on Biological Therapy·Giacomo CaldarolaClara De Simone
Jul 31, 2020·Journal of the American Academy of Dermatology·Nikolai LoftLone Skov
Feb 18, 2021·RMD Open·Roberta RamondaUNKNOWN on behalf Spondyloartritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”
Mar 2, 2021·Frontiers in Immunology·Sabrina PortaFrancisco Capani
Mar 20, 2021·Therapeutic Advances in Musculoskeletal Disease·Paras KarmacharyaLihi Eder
Jul 27, 2021·Expert Opinion on Drug Safety·Bénédicte CaronLaurent Peyrin-Biroulet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.

Candida albicans

Candida albicans is an opportunistic, fungal pathogen of humans that frequently causes superficial infections of oral and vaginal mucosal surfaces of debilitated and susceptible individuals. Discover the latest research on Candida albicans here.

Candidiasis

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.

Candidiasis (ASM)

Candidiasis is a common fungal infection caused by Candida and it can affect many parts for the body including mucosal membranes as well as the gastrointestinal, urinary, and respiratory tracts. Here is the latest research.